Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Cutaneous sarcoidosis Indication Strategy Report 2026: TNF, Trials and Deals
24 July 2026
2026 Cutaneous sarcoidosis strategy: epidemiology, TNF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Pityriasis rosea Indication Strategy Report 2026: HHV-6, Trials and Deals
24 July 2026
2026 Pityriasis rosea strategy: epidemiology, HHV-6 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Pityriasis lichenoides Indication Strategy Report 2026: TNF, Trials and Deals
24 July 2026
2026 Pityriasis lichenoides strategy: epidemiology, TNF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Eosinophilic pustular folliculitis Indication Strategy Report 2026: PGD2 receptor, Trials and Deals
24 July 2026
2026 Eosinophilic pustular folliculitis strategy: epidemiology, PGD2 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Calcinosis cutis Indication Strategy Report 2026: ENPP1, Trials and Deals
24 July 2026
2026 Calcinosis cutis strategy: epidemiology, ENPP1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Livedoid vasculopathy Indication Strategy Report 2026: Factor Xa, Trials and Deals
24 July 2026
2026 Livedoid vasculopathy strategy: epidemiology, Factor Xa biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Chilblain lupus erythematosus Indication Strategy Report 2026: STING, Trials and Deals
24 July 2026
2026 Chilblain lupus erythematosus strategy: epidemiology, STING biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Urticarial vasculitis Indication Strategy Report 2026: C5a receptor, Trials and Deals
24 July 2026
2026 Urticarial vasculitis strategy: epidemiology, C5a receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cutaneous small vessel vasculitis Indication Strategy Report 2026: Complement C5a, Trials and Deals
24 July 2026
2026 Cutaneous small vessel vasculitis strategy: epidemiology, Complement C5a biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Polyarteritis nodosa Indication Strategy Report 2026: TNF, Trials and Deals
24 July 2026
2026 Polyarteritis nodosa strategy: epidemiology, TNF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Kawasaki disease Indication Strategy Report 2026: IL-1 beta, Trials and Deals
24 July 2026
2026 Kawasaki disease strategy: epidemiology, IL-1 beta biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Kikuchi disease Indication Strategy Report 2026: IFN-gamma, Trials and Deals
24 July 2026
2026 Kikuchi disease strategy: epidemiology, IFN-gamma biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…